Quantinno Capital Management LP Boosts Stock Position in Replimune Group, Inc. $REPL

Quantinno Capital Management LP lifted its stake in Replimune Group, Inc. (NASDAQ:REPL) by 782.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 108,477 shares of the company’s stock after purchasing an additional 96,188 shares during the quarter. Quantinno Capital Management LP’s holdings in Replimune Group were worth $830,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. SummitTX Capital L.P. grew its holdings in Replimune Group by 165.5% in the 1st quarter. SummitTX Capital L.P. now owns 288,889 shares of the company’s stock valued at $2,210,000 after buying an additional 180,086 shares in the last quarter. Walleye Capital LLC raised its holdings in shares of Replimune Group by 3.2% during the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after acquiring an additional 2,192 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Replimune Group by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after acquiring an additional 20,742 shares during the last quarter. Candriam S.C.A. acquired a new position in shares of Replimune Group during the 1st quarter valued at about $3,014,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Replimune Group in the first quarter valued at about $528,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on REPL. JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research note on Wednesday, August 12th. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Finally, Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $11.00 to $17.00 in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.86.

Replimune Group Price Performance

Replimune Group stock opened at $14.63 on Tuesday. The company’s 50 day simple moving average is $10.77 and its 200-day simple moving average is $7.84. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $15.70. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -4.64 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, equities research analysts expect that Replimune Group, Inc. will post -2.7 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Emily Luisa Hill sold 11,448 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,480.56. Following the transaction, the chief financial officer owned 225,108 shares of the company’s stock, valued at approximately $2,919,650.76. This represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 81,868 shares of company stock valued at $1,017,068 over the last ninety days. 5.40% of the stock is owned by insiders.

Replimune Group Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.